Barcelona, Spain

Julian Garcia-Rafanell


Average Co-Inventor Count = 8.8

ph-index = 3

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 1995-1998

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Julian Garcia-Rafanell: Advancements in Pharmaceutical Development

Introduction

Julian Garcia-Rafanell is a notable inventor based in Barcelona, Spain, recognized for his contributions to pharmaceutical innovations. With a total of three patents to his name, Garcia-Rafanell has significantly advanced the treatment of various medical conditions through his groundbreaking work.

Latest Patents

One of Julian’s latest patents pertains to "Azo derivatives of 5-aminosalicylic acid." This invention focuses on the treatment of PAF (platelet-activating factor) and histamine-mediated diseases. Another notable patent is for a compound described as "8-chloro-11-[1-[(5-methyl-3-pyridyl)methyl]-4-piperidyliden]-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine." This pharmaceutical composition acts as a dual PAF antagonist and antihistamine, showcasing Garcia-Rafanell's innovative approach to drug development.

Career Highlights

Julian Garcia-Rafanell is affiliated with J. Uriach & Cia, S.A., a prominent company that emphasizes innovation in the pharmaceutical sector. His role there allows him to continually explore and develop new therapeutic solutions that can impact patient care and treatment.

Collaborations

Throughout his career, Julian has collaborated with talented professionals, including Elena Carceller and Carmen Almansa. These partnerships are essential in fostering an environment of innovation and excellence in pharmaceutical research and development.

Conclusion

Julian Garcia-Rafanell's commitment to advancing pharmaceutical science through his patents underscores the vital role of inventors in healthcare innovation. His work not only paves the way for new treatments but also exemplifies the collaborative nature of research in the field. With ongoing contributions, Julian’s endeavors will undoubtedly continue to influence the pharmaceutical landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…